Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 23, 2006
Reporting Period: Events occurring on October 15, 2006, and November 23, 2006.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance and equity compensation actions.
Material Changes and Events
- Adoption of 2006 Option Plan: On October 15, 2006, the company adopted a stock option plan for directors and employees, reserving 3,000,000 shares of common stock.
- Grant of Stock Options: On November 23, 2006, the company granted options to three officers/directors and one consultant.
- Grant Details:
- Total shares covered: 1,950,000.
- Exercise price: $0.76 per share.
- Term: Exercisable until November 22, 2009 (3-year period).
- Vesting: Subject to terms in the specific stock option agreements.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of unregistered sales of equity securities under Item 3.02.
Investor Verification Checklist
- Verify the vesting schedule details in the attached Exhibit 10.2 (Form of stock option agreement).
- Confirm the total number of shares reserved under the 2006 Option Plan (3,000,000) versus the shares granted in this specific transaction (1,950,000).
- Review the company's capitalization table to assess the dilution impact of the 1,950,000 new options.
- Check subsequent filings for any changes to the exercise price or vesting conditions.